130 related articles for article (PubMed ID: 38682846)
1. Antifungal susceptibility of molecularly confirmed Aspergillus species from clinical samples.
Tzar MN; Mustakim S; Yusoff H; Tap RM
Malays J Pathol; 2024 Apr; 46(1):71-78. PubMed ID: 38682846
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
3. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
4. Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
Toyotome T; Saito S; Koshizaki Y; Komatsu R; Matsuzawa T; Yaguchi T
J Infect Chemother; 2020 Feb; 26(2):321-323. PubMed ID: 31564504
[TBL] [Abstract][Full Text] [Related]
5. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S
Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
8. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J;
Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.
Mello E; Posteraro B; Vella A; De Carolis E; Torelli R; D'Inzeo T; Verweij PE; Sanguinetti M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416538
[TBL] [Abstract][Full Text] [Related]
10. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999.
Chandrasekar PH; Cutright JL; Manavathu EK
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):211-4. PubMed ID: 11777662
[TBL] [Abstract][Full Text] [Related]
11. A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns.
Castro C; Galán-Sanchez F; Linares MJ; Tejero R; Ruiz M; Serrano ML; Rodríguez-Iglesias M; Martín-Mazuelos E;
Med Mycol; 2019 Jun; 57(4):412-420. PubMed ID: 30289467
[TBL] [Abstract][Full Text] [Related]
12. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
[TBL] [Abstract][Full Text] [Related]
13. Antifungal Susceptibility of the Aspergillus viridinutans Complex: Comparison of Two
Lyskova P; Hubka V; Svobodova L; Barrs V; Dhand NK; Yaguchi T; Matsuzawa T; Horie Y; Kolarik M; Dobias R; Hamal P
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437620
[TBL] [Abstract][Full Text] [Related]
14. Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico.
Treviño-Rangel RJ; Villanueva-Lozano H; Bonifaz A; Castañón-Olivares LR; Andrade A; Becerril-García MA; Martínez-Reséndez MF; Ayala-Gaytán J; Montoya AM; González GM
Med Mycol; 2021 Oct; 59(10):1006-1014. PubMed ID: 34021564
[TBL] [Abstract][Full Text] [Related]
15. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China.
Jing R; Yang WH; Xiao M; Li Y; Zou GL; Wang CY; Li XW; Xu YC; Hsueh PR
J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
Badali H; Fakhim H; Zarei F; Nabili M; Vaezi A; Poorzad N; Dolatabadi S; Mirhendi H
Mycopathologia; 2016 Apr; 181(3-4):235-40. PubMed ID: 26615417
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
18. Drug Sensitivity and Resistance Mechanism in Aspergillus Section
Hashimoto A; Hagiwara D; Watanabe A; Yahiro M; Yikelamu A; Yaguchi T; Kamei K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607016
[No Abstract] [Full Text] [Related]
19. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates.
Reichert-Lima F; Lyra L; Pontes L; Moretti ML; Pham CD; Lockhart SR; Schreiber AZ
Mycoses; 2018 Jun; 61(6):360-365. PubMed ID: 29468746
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
